<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SOLIFENACIN SUCCINATE</span><br/>(sol-i-fen'a-sin)<br/><span class="topboxtradename">VESIcare<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic</span>; <span class="classification">parasympatholytic</span>; <span class="classification">antimuscarinic</span>; <span class="classification">antispasmodic</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Solifenacin is a selective muscarinic antagonist that depresses both voluntary and involuntary bladder contractions caused
         by detrusor overactivity.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Solifenacin improves the volume of urine per void and reduces the frequency of incontinent and urgency episodes.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to solifenacin or any component of its formulations; severe hepatic impairment; pregnancy (category C); gastric
         retention; uncontrolled narrow-angle glaucoma; urinary retention; toxic megacolon; GI obstruction; ileus; GERD.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Bladder outflow obstruction; concurrent use of ketoconazole or other potent CYP3A4 inhibitors; obstructive disorders; decreased
         GI motility; hepatic impairment; history of QT prolongation or concurrent use of medications known to prolong the QT interval;
         controlled narrow-angle glaucoma; renal impairment; renal disease; renal failure; mild to moderate hepatic impairment; older
         adults.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Overactive Bladder</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 5 mg once daily; may be increased to 10 mg once daily if tolerated (max of 5 mg/d if taking drugs that inhibit CYP3A4see
               Interactions, Drug)<br/><br/><span class="impairmenttitle">Adjustment for Hepatic Impairment</span><br/>If moderate hepatic impairment, does not exceed 5 mg/d. If severe hepatic impairment, do not use.<br/><br/><span class="impairmenttitle">Adjustment for Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Tablets should be swallowed whole.</li>
<li>Store at 1530° C (5986° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Edema, fatigue. <span class="typehead">CNS<b></b> 			:</span> Dizziness, depression. <span class="typehead">CV<b></b> 			:</span> Hypertension. <span class="typehead">GI<b></b> 			:</span> <span class="speceff-common">Dry mouth, constipation</span> <i>,</i> nausea, vomiting, dyspepsia, upper abdominal pain. <span class="typehead">Respiratory<b></b> 			:</span> Cough. <span class="typehead">Special Senses:</span> Blurred vision, dry eyes. <span class="typehead">Urogenital<b></b> 			:</span> Urinary tract infection, urinary retention. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug<b></b> 			:</span> <span class="classification">cyp3a4 inhibitors</span> (e.g., <b>clarithromycin, delavirdine, diltiazem, efavirenz, erythromycin, fluconazole, fluvoxamine, itraconazole, nefazodone, norfloxacin,
         omeprazole</b> <b>,</b> <span class="classification">protease inhibitors</span>, <b>quinine, verapamil, troleandomycin, voriconazole, zafirlukast</b>) may increase levels and toxicity (max dose 5 mg/d); <b>amantadine, amoxapine, bupropion, clozapine, cyclobenzaprine, diphenhydramine, disopyramide, maprotiline, olanzapine, orphenadrine</b> <b>,</b> <span class="classification">phenothiazines, tricyclic antidepressants</span> have additive anticholinergic adverse effects. <span class="typehead">Food<b></b> 			:</span> <b>Grapefruit juice</b> may increase solifenacin levels and toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption<b></b> 			:</span> 90% absorbed from GI tract. <span class="typehead">Peak<b></b> 			:</span> 38 h. <span class="typehead">Metabolism<b></b> 			:</span> Extensively metabolized in the liver by CYP3A4. <span class="typehead">Elimination<b></b> 			:</span> Primarily excreted in urine, 22% excreted in feces. <span class="typehead">Half-Life:</span> 4568 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor ECG in patients with a known history of QT prolongation or patients taking medications that prolong the QT interval.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Stop taking this drug and report to physician if urinary retention occurs.</li>
<li>Report promptly any of the following: blurred vision or difficulty focusing vision, palpitations, confusion, or severe dizziness.</li>
<li>Report to physician problems with bowel elimination, especially constipation lasting 3 or more days.</li>
<li>Exercise caution in hot environments, as the risk of heat prostration increases with this drug.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>